News
Building Scalable API Programs in a Changing Pharmaceutical Landscape: Meet Olon USA at AAPS PharmSci 360
Pharmaceutical companies advancing API programs from preclinical development into clinical trials and commercial manufacturing face technical and financial…
Olon USA Brings Global API Development and Manufacturing Capabilities to CPHI Milan 2026
Pharmaceutical and biotech companies are evaluating development and manufacturing strategies against a changing funding environment, evolving supply-chain requirements,…
Building a More Resilient API Supply Chain: How Olon USA’s Global Manufacturing Network Supports Reshoring and Dual-Sourcing
Pharmaceutical supply chains do more than move materials between manufacturing sites and the marketplace. They help ensure patients…
Leveraging Olon’s API Experience to De-Risk Your Innovative Molecule
Developing an innovative molecule requires more than demonstrating promising biological activity. Success depends on building a development strategy…
An Exciting Announcement from Olon USA: Expansion in Concord, Ohio is Building the Future of U.S. API Manufacturing
Olon USA’s global leadership in Milan, Italy has officially announced the completion of a major expansion at its…
BIO International Conference 2026: Building Flexible Development and Manufacturing Strategies for a Changing Biopharmaceutical Market
The biopharmaceutical industry continues to navigate a complex development environment. Funding pressures, evolving supply chain strategies, geographic risk…
How Early API Strategy Can Reduce Your Cost, Risk, and Development Delays
In pharmaceutical development, sponsors often focus heavily on clinical milestones, toxicology readiness, or formulation strategy. But long before…
Why API Development Should Be at the Center of Your CMC Strategy
For many emerging pharmaceutical and biotech companies, the transition from discovery into IND-enabling work can feel deceptively straightforward.…
From Route Scouting to Route Optimization: IND-Enabling API Development at Olon USA
Route scouting and route optimization are foundational to IND-enabling API development. Early synthetic decisions determine whether a program…
From Molecular Biology to Business Development: A Conversation with Laura Milbrandt
Laura Milbrandt’s background is rooted in molecular biology and biotechnology. She entered the field with a clear focus…
Olon USA Showcases Expanded CDMO Capabilities at CPhI Americas 2026
Olon USA and Olon SpA will participate in CPhI Americas 2026, taking place June 2–4, 2026, at the…
From IND to Commercial: Why Integrated API Development Is the New Standard
The traditional approach to API development has long relied on a fragmented network of partners. One organization supports…
The Coming API Capacity Crunch: Why Sponsors Must Secure U.S. Manufacturing Now
Over the past year, many organizations across the pharmaceutical and biotech landscape have taken a more cautious approach…
Meeting the Moment for the Life Sciences Industry: Why Strategic API Manufacturing Matters More Than Ever
The pharmaceutical industry has entered a phase defined by discipline and precision. Capital is more selective, pipelines are…
Olon USA at DCAT Week: Global Scale, Local Execution, and What’s Next for 2026
This month, the Olon USA team will be on the ground in DCAT Week, meeting with partners and…
Olon USA is Expanding U.S. API Manufacturing Capacity While Supporting Clinical and Commercial Programs in 2026
As the pharmaceutical industry moves deeper into 2026, one of the most consistent themes shaping sponsor decisions is…
Olon USA in San Francisco for JPM Week: Connecting with Biopharma Leaders Driving the Future of Healthcare
Each January, San Francisco becomes the epicenter of the global biopharmaceutical industry as executives, innovators, and investors gather…
Positioned for the Next Wave the Industry Brings: How Olon USA Is Preparing for Renewed API Investment in 2026
Over the last several years, the pharmaceutical industry has grown accustomed to volatility. What many expected to be…
What Sponsors Should Know When Preparing an IND in 2026
The IND landscape is shifting after a period of constrained early-stage funding and reduced activity. Grants and private…
Navigating the New Drug Application (NDA): From Clinical Trials to Commercial Approval
For any emerging or established drug developer, the New Drug Application (NDA) represents the pivotal final step in…
Investing in the Future: Olon’s Expanding Capabilities in High-Potency and Bioconjugation
A Long-Term Vision for Advanced Therapeutics At Olon, innovation doesn’t just happen in the laboratory — it’s built…
Olon USA Heads to AAPS PharmSci 360 2025, Highlighting A New Era of Integrated Global Manufacturing
Olon USA is proud to announce its participation in this year’s AAPS PharmSci 360, taking place November 9–12,…
Join Olon at CPhI Frankfurt
Visit us at CPhI Europe, October 28–30 at Messe Frankfurt, and experience Olon as one unified, fully integrated…
Olon USA Earns FDA Green Light for Two Commercial APIs, Strengthening Its U.S. Manufacturing Base
Concord, Ohio – October 2025 — Olon USA has reached another major milestone in its continued growth and…
Navigating Regulatory Change in API Development: How Olon and Olon USA Keep Sponsors a Step Ahead
Global API development is evolving fast—and not always in sync. From stricter filing pathways in China and Brazil…
Why Emerging Pharma Startups Choose to Partner with Olon USA as their CDMO
Emerging pharma companies face a critical decision early in their journey: invest in internal infrastructure or partner with…
Olon USA to Exhibit at Contract Pharma Conference 2025
Olon USA will exhibit at the 24th Annual Contract Pharma Conference in New Brunswick, New Jersey, on September…
Ohio’s Biotech Network: Accelerating Drug Development with an End-to-End Ecosystem
Ohio’s life sciences industry has scaled into one of the most comprehensive biotech and pharmaceutical ecosystems in the…
How Process Analytical Technology (PAT) Enhances API Manufacturing at Olon USA
Process Analytical Technology (PAT) is integrated into every stage of API development at Olon USA. By applying PAT…
Global Expertise, Local Focus: Olon USA’s Strategic Advantage in Generics
Olon USA supports the pharmaceutical market with a robust generics portfolio, a deep bench of technical expertise, and…
From Momentum to Meaningful Connections: Olon USA Heads to BIO International
Fresh off a high-energy showing at CPHI North America, the Olon USA and Olon Italy teams are keeping…
Post-Show Reflections from CPHI Americas: Olon USA Responds to Industry Shifts with Resilience and Strategy
As the pharma world wraps up another CPHI event—this time in Philadelphia—Olon USA takes a moment to reflect…
Olon USA and Olon S.p.A to Showcase API and CDMO Expertise at CPHI Americas 2025
Olon USA, together with Olon S.p.A, will exhibit at CPHI Americas 2025, taking place May 20–22 at the…
Built to Scale: How Olon USA Optimizes API Scale-Up for Long-Term Success
When it comes to Active Pharmaceutical Ingredient (API) development, success doesn’t stop at discovery—it hinges on scale-up. At Olon…
Key Takeaways from DCAT Week 2025, from CEO of Olon USA, Robert Poe
DCAT Week 2025, held from March 17–20 in New York City, convened leaders from the pharmaceutical and biotech…
Olon USA Strengthens Its Commitment to Cancer Research at AACR Annual Meeting
Olon USA will be exhibiting at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois,…
Choosing the Right CDMO: What Pharma Companies Should Look For
Selecting a contract development and manufacturing organization (CDMO) is a critical decision for pharmaceutical companies. The right partner…
Pre-development Strategies for Your Drug Development Project in 2025
As we move into 2025, many companies are beginning the drug development journey. Whether you’re starting a new…
Meet Olon’s Worldwide Team in New York During DCAT Week
The pharmaceutical industry’s premier networking event, DCAT Week 2025, is just around the corner, taking place in New…
Olon USA is in San Francisco for the 43rd JP Morgan Healthcare and 2025 Biotech Showcase
Olon USA is enjoying an exciting week in San Francisco, where we are attending two key events for…
Streamlining High Potency API Development for 2025 and Beyond
The pharmaceutical landscape is evolving rapidly, driven by shifting global policies, economic pressures, and advancing technologies. Olon USA…
Olon USA’s Advanced High-Potency API Suite: Meeting Complex Challenges in Drug Development
Olon USA’s high-potency API (HPAPI) suite is designed to meet the complex needs of modern pharmaceutical development. With…
OLON RELEASES ITS ANNUAL ESG REPORT
OLON RELEASES ITS ANNUAL ESG REPORT The Italian Group, leading international API supplier, presents the 2023 sustainability report…
Olon is ready to host productions in the new facility dedicated to ultra-potent compounds
Olon is ready to host productions in the new facility dedicated to ultra-potent compounds Milan, Italy – 4th…
Mastering the First-Time Scale-Up: Olon USA’s Proven Approach to First-Time Scale-Ups
The first time an API is produced at a production scale is an exciting and critical period in…
Olon USA Prepares for AAPS PharmSci 360: Showcasing API Development Expertise
As Olon USA gears up for AAPS PharmSci 360 in Salt Lake City from October 20-23, 2024, we’re…
Enhancing Drug Innovation Through the Power of Small-Scale Chemistry
Reliable drug discovery and development is essential in the quickly changing biotech and pharmaceutical industries. Small-scale chemistry plays…
Flexible API Production: How Our Kilo Lab at Olon USA Supports Small Pharma
The pharmaceutical industry is constantly evolving. A key part of a pharmaceutical company’s success is both efficient and…
OLON CONTINUES ITS GROWTH PATH AND ANNOUNCES A NEW ACQUISITION
OLON CONTINUES ITS GROWTH PATH AND ANNOUNCES A NEW ACQUISITION Olon, the leading chemical-pharmaceutical group in the production…
Olon USA’s Expertise in Custom Stable-Labeled Bioanalytical Standards for Drug Development
Olon USA’s expertise in stable labeling empowers clients to develop cost-effective and precise bioanalytical internal standards. As a…